 Stock (OTC:HEPZF), Trade Ideas

Rosenblatt analyst Andrew Bond maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Buy and lowers the price target from $82 to $76.

News

Price Target

Analyst Ratings

NDAQ

Rosenblatt Maintains Buy on Nasdaq, Lowers Price Target to $76

WIIM

Skechers USA shares ares trading higher after the company reported better-than-expected Q1 financial results.

Additionally, based on the Company&#39;s current forecast for light vehicle production for calendar year 2025, the Company still expects calendar year 2025 revenue of approximately&nbsp;$2.65&nbsp;-&nbsp;$2.75 billion.

Guidance

GNTX

Gentex Continues To See 2024 Revenue Of $2.45B-$2.55B, Est $2.516B

– Additional Data in Pregnant Adults Who Are Virologically Suppressed Reinforce Safety and Tolerability Profile of Biktarvy in Broad Range of People With HIV –
– Perinatal Guidelines Recognize Biktarvy as Alternative Regimen for Use During Pregnancy and for Those Trying to Conceive –
Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy&#xAE; (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads. These additional data stem from Study 5310, which evaluated the pharmacokinetics, safety and efficacy of Biktarvy in pregnant PWH who have suppressed viral loads and no known resistance to any components of Biktarvy in their second and third trimesters and through a median of 16 weeks postpartum. This update makes Biktarvy the only second-generation integrase strand transfer inhibitor (INSTI)-based single-tablet regimen (STR) with in-label clinical trial data and FDA approval in virologically suppressed adults who are pregnant. The U.S. Department of Health and Human Services (DHHS) perinatal guidelines recognize Biktarvy as having sufficient data to support being recommended as an alternative complete regimen for use in pregnancy and for people who are trying to conceive. Additionally, guidelines recommend continuing Biktarvy for PWH already on treatment who are virologically suppressed and tolerating treatment well who may become pregnant.
"This label update marks an important milestone for Biktarvy, reinforcing its efficacy profile for pregnant PWH, an often understudied and most vulnerable community in clinical research," said Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences. "Not only is Biktarvy an alternative regimen for use in pregnancy, but people of childbearing potential can also remain on Biktarvy if they become pregnant. We continue to keep people at the center of our tireless commitment to HIV treatment research and development so that our medicines address the needs of the broad range of communities that we serve."
The updated label now includes additional data from Study 5310, a Phase 1b, open-label, single-arm, multicenter clinical trial evaluating the pharmacokinetics, safety and efficacy of Biktarvy in pregnant PWH who were virologically suppressed (HIV-1 RNA &lt; 50 copies/mL) and had no known resistance to the components of Biktarvy. Participants were administered Biktarvy once daily from the second or third trimester through postpartum. Lower plasma exposures of Biktarvy were observed during pregnancy as compared to postpartum; all 32 participants who completed the study maintained viral suppression during pregnancy, at delivery and through week 18 postpartum. The median CD4+ cell count at baseline was 558 cells/μL, and the median change in CD4+ cell count from baseline to week 12 postpartum was 159 cells/μL. All 29 newborn participants had negative/nondetectable HIV-1 PCR results at birth and/or at four to eight weeks post birth. Further, the study did not identify any new safety or tolerability concerns for people who use Biktarvy during pregnancy and postpartum as the overall incidence and types of adverse events observed were consistent with those expected for the population studied.
This label update marks a significant milestone in Gilead's efforts to address the individual needs of all people impacted by HIV, as these data can help to provide assurance for people of childbearing potential to remain on Biktarvy if they were to become pregnant. The Biktarvy label was also updated in February 2024 to align with Centers for Disease Control and Prevention (CDC) guidance on breastfeeding, which encourages a dialogue between a person and their healthcare provider regarding breastfeeding.
"As an OB-GYN and a longtime women's health advocate, I'm incredibly passionate about helping end health disparities among women, and especially Black women who are disproportionately impacted by HIV," said Yolanda M. Lawson, MD, President, National Medical Association. "I'm encouraged by the tremendous progress made in personalizing HIV treatment over the years, including this milestone that further supports the safety profile of Biktarvy use during pregnancy. Together, we can help bring all PWH the care they need, including those who are or may become pregnant, so they can continue to live longer, healthier lives while on HIV treatment."
"These additional data can help to better inform treatment decisions between pregnant PWH and their providers and mark an incredible step forward in addressing the unique needs PWH have when they are pregnant or planning to become pregnant," said William R. Short, MD, Associate Professor of Medicine, Perelman School of Medicine at the University of Pennsylvania. "As experts in perinatal care, we will continue to recommend ways pregnant PWH can maintain undetectable viral loads so they can stay healthy and prevent transmission to their baby."
Please see below for U.S. Indications and Important Safety Information for Biktarvy, including Boxed Warning.
There is no cure for HIV or AIDS.

Biotech

General

GILD

FDA Approves Biktarvy Label Update With Data For Pregnant Adults With HIV; Perinatal Guidelines Recognize Biktarvy As Alternative Regimen For Use During Pregnancy And For Those Trying To Conceive

EXPO

Exponent shares are trading higher after the company reported better-than-expected Q1 financial results.

Baird analyst Eric Coldwell maintains Laboratory Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Outperform and lowers the price target from $255 to $244.

Laboratory Corporation Of America Holdings

Baird Maintains Outperform on Laboratory Corp, Lowers Price Target to $244

VINC

Vincerx Pharma shares are trading lower after the company announced a proposed underwritten public offering of common stock and warrants.

ROKU

Roku shares are trading lower, reversing after gaining late Thursday on Q1 earnings.

iClick Interactive Asia Group Limited ("iClick" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLK#NASDAQ">ICLK</a>), a leading enterprise and marketing cloud platform in China that empowers worldwide brands with full-stack consumer lifecycle solutions, today announced the termination of the previously announced agreement and plan of merger, dated as of November 24, 2023 (the "Merger Agreement"), by and among the Company, TSH Investment Holding Limited (the "Parent") and TSH Merger Sub Limited (the "Merger Sub").
&nbsp;
On March 29, 2024, the Company delivered to the Parent a notice (the "Closing Notice") confirming the satisfaction of the closing conditions under the Merger Agreement (other than those conditions that by their nature are to be satisfied by actions taken at the Closing as defined below) and that the Company is ready, willing and able to consummate the closing contemplated under the Merger Agreement (the "Closing").&nbsp; Since the delivery of the Closing Notice, the Company has been communicating and cooperating with the Parent, Merger Sub and their representatives towards the Closing, but the Parent and Merger Sub have failed to complete the Closing within ten (10) Business Days following the delivery date of the Closing Notice pursuant to Section 8.03(b) of the Merger Agreement.&nbsp;
On April 26, 2024, the Company (acting upon the recommendation of the Special Committee) sent a notice of termination to the Parent and the Merger Sub pursuant to Section 8.03(b) of the Merger Agreement, notifying the Parent and the Merger Sub that the Company is exercising its right to terminate the Merger Agreement pursuant to Section 8.03(b) of the Merger Agreement and demanding the Parent to pay the US$1,800,000 termination fee pursuant to Section 8.06(b) of the Merger Agreement by May 9, 2024.&nbsp; &nbsp;As a result of the termination of the Merger Agreement, the proposed merger will not be completed.&nbsp;

Contracts

ICLK

iClick Interactive Asia Group Limited Announces Termination Of Merger Agreement

Baird analyst Eric Coldwell maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Outperform and raises the price target from $362 to $363.

ICLR

Baird Maintains Outperform on Icon, Raises Price Target to $363

Rosenblatt analyst Barton Crockett maintains Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) with a Neutral and raises the price target from $12 to $14.

SNAP

Rosenblatt Maintains Neutral on Snap, Raises Price Target to $14

&quot;Fiscal year 2024 is shaping up to be another great year of financial performance, and we&#39;re on track to achieve our long-term financial targets,&quot; said Jennifer Walter, CFO. &quot;This year, our sales will grow by&nbsp;7%, our adjusted operating margin will expand by 150 basis points and our adjusted earnings per share will increase by&nbsp;18%.&quot;

MOG/A

Moog Raised FY24 Net Sales Outlook To $3.55B (From $3.50B) Vs. $3.51B Est.; Adj. EPS to $7.25 (From $6.90) Vs. $6.94 Est.

Trinet Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNET#NYSE">TNET</a>) reported quarterly earnings of $2.16 per share which missed the analyst consensus estimate of $2.46 by 12.2 percent. This is a 13.25 percent decrease over earnings of $2.49 per share from the same period last year. The company reported quarterly sales of $1.26 billion which missed the analyst consensus estimate of $1.27 billion by 0.47 percent. This is a 1.44 percent increase over sales of $1.25 billion the same period last year.

Earnings

Earnings Misses

TNET

Trinet Group Q1 Adj $2.16 Misses $2.46 Estimate, Sales $1.26B Miss $1.27B Estimate

Baird analyst Michael Bellisario maintains Wyndham Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WH#NYSE">WH</a>) with a Outperform and raises the price target from $86 to $88.

Baird Maintains Outperform on Wyndham Hotels & Resorts, Raises Price Target to $88

Rosenblatt analyst Blair Abernethy maintains Pegasystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) with a Buy and maintains $75 price target.

PEGA

Rosenblatt Maintains Buy on Pegasystems, Maintains $75 Price Target

GrafTech International shares are trading higher after the company reported better-than-expected Q1 financial results.

Baird analyst Peter Benedict downgrades Hibbett (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIBB#NASDAQ">HIBB</a>) from Outperform to Neutral and raises the price target from $80 to $87.5.

Downgrades

HIBB

Baird Downgrades Hibbett to Neutral, Raises Price Target to $87.5

Gentex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTX#NASDAQ">GNTX</a>) reported quarterly earnings of $0.47 per share which met the analyst consensus estimate. This is a 11.9 percent increase over earnings of $0.42 per share from the same period last year. The company reported quarterly sales of $590.225 million which missed the analyst consensus estimate of $598.011 million by 1.30 percent. This is a 7.17 percent increase over sales of $550.761 million the same period last year.

Gentex Q1 2024 GAAP EPS $0.47, Inline, Sales $590.225M Miss $598.011M Estimate

Rosenblatt analyst Barton Crockett maintains Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Neutral and maintains $89 price target.